GRFS 📈 Grifols SA ADR - Overview

Grifols, S.A. is a plasma therapeutic company with a global presence, operating in Spain, the United States, Canada, and internationally. The company's product portfolio includes a range of plasma-derived therapies, such as immunoglobulin to treat immunodeficiencies, albumin to restore circulatory volume and protein loss in conditions like liver cirrhosis and severe burns, and alpha-1 proteinase inhibitor to treat the genetic disease alpha-1. Additionally, Grifols offers clotting factors like factor VIII and factor IX to treat hemophilia A and B, as well as von Willebrand's disease. The company also provides antithrombin III to treat hereditary antithrombin deficiency and Fostamatinib, a spleen tyrosine kinase inhibitor.

Grifols' product line extends to combination therapies, such as a combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding. The company also offers plasma exchange with albumin to treat Alzheimer's disease, which is a unique approach to addressing this complex condition. Furthermore, Grifols markets diagnostic testing equipment, reagents, and other equipment, as well as biological products, and manufactures and sells plasma to third parties. The company's research activities are focused on developing new treatments, and it also markets pharmaceutical products for hospital pharmacies.

The company has a robust pipeline of products in various stages of development, including Xembify Pre-filled syringes, FlexBag, and Prolastin vials in Phase IV development, and Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development. Grifols is also working on AKST4290, which is in Phase II clinical development. The company offers a range of other products, including recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. Grifols has collaboration agreements with Canadian Blood Services and GIANT, as well as GigaGen, to develop recombinant polyclonal immunoglobulin therapies.

With a history dating back to 1909, Grifols is headquartered in Barcelona, Spain, and has established itself as a leading player in the biotechnology industry. The company's common stock is listed on the NASDAQ exchange under the ticker symbol GRFS, and its ISIN is US3984384087. As a biotechnology company, Grifols is focused on developing innovative treatments that address complex medical conditions, and its products have the potential to improve the lives of patients around the world. The company's website, https://www.grifols.com, provides more information on its products, research activities, and mission.